EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ryvu Therapeutics's enterprise value is zł947.68 Mil.
Ryvu Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was zł55.61 Mil. Therefore, Ryvu Therapeutics's EV-to-Revenue for today is 17.04.
The historical rank and industry rank for Ryvu Therapeutics's EV-to-Revenue or its related term are showing as below:
WAR:RVU'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9 Med: 10.18 Max: 1110.17
Current: 17.04
During the past 13 years, the highest EV-to-Revenue of Ryvu Therapeutics was 1110.17. The lowest was 0.90. And the median was 10.18.
WAR:RVU's EV-to-Revenue is ranked worse than 64.99% of 1034
companies
in the Biotechnology industry
Industry Median: 7.69
vs WAR:RVU: 17.04
The historical data trend for Ryvu Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ryvu Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Ryvu Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's EV-to-Revenue falls into.
Ryvu Therapeutics's current Enterprise Value is zł947.68 Mil.
Ryvu Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł55.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics's share price for today is zł50.10.
Ryvu Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ryvu Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WAR:RVU has been successfully added to your 